Oncolytics Biotech (TSE:ONC) Director Buys C$29,250.00 in Stock

Oncolytics Biotech Inc. (TSE:ONC) Director Deborah Brown bought 25,000 shares of the stock in a transaction dated Thursday, February 12th. The shares were bought at an average cost of C$1.17 per share, with a total value of C$29,250.00. Following the completion of the purchase, the director directly owned 109,851 shares of the company’s stock, valued at approximately C$128,525.67. This trade represents a 29.46% increase in their position.

Oncolytics Biotech Stock Performance

Oncolytics Biotech Inc. has a 12-month low of C$0.44 and a 12-month high of C$2.08. The firm has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The business’s 50-day simple moving average is C$14.90 and its two-hundred day simple moving average is C$13.02.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. On average, equities analysts forecast that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.